Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Rampal on Tools to Estimate Prognosis in Myelofibrosis

October 13th 2020

Raajit K. Rampal, MD, PhD, discusses available tools to estimate prognosis in myelofibrosis.

Dr. Nazha on the Risk of Progression to Myelofibrosis in Polycythemia Vera

October 9th 2020

Aziz Nazha, MD, discusses the risk of progression to myelofibrosis in patients with polycythemia vera.

Dr. Pemmaraju on the Potential Role of Novel Therapies in MPNs

October 8th 2020

Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.

Dr. Verstovsek on the Different Phases of MPNs

October 6th 2020

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

Dr. Masarova on the Safety of JAK Inhibitor/Targeted Therapy Combos in Myelofibrosis

October 5th 2020

Lucia Masarova, MD, discusses the toxicities associated with the combination of JAK inhibitors and other targeted therapies in patients with myelofibrosis.

Pacritinib NDA Submission Planned for Myelofibrosis With Severe Thrombocytopenia

October 1st 2020

An agreement has been reached to submit a new drug application for the potential accelerated approval of the JAK2/FLT3 inhibitor pacritinib for use in patients with myelofibrosis and severe thrombocytopenia.

Dr. Rampal on Challenges With Targeting High-Risk Mutations in Myelofibrosis

September 28th 2020

Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.

Dr. Mascarenhas on the Need to Develop Curative Therapies in Myelofibrosis

September 25th 2020

John O. Mascarenhas, MD, discusses the need to develop curative therapies in myelofibrosis.

Myelofibrosis Paradigm Slated to Expand With Investigative Therapies Showing Potential

September 25th 2020

The myelofibrosis paradigm is bursting with novel agents and combinations that have been developed with the ultimate goal of helping patients live longer.

Dr. Rampal on the Evolving Understanding of Genomic Alterations in MPNs

September 24th 2020

Raajit K. Rampal, MD, PhD, discusses the evolving understanding of genetic alterations in myeloproliferative neoplasms.

Retrospective Study Shows Inferior OS and Symptom Response in RAS/CBL-Mutant Myelofibrosis

September 24th 2020

The presence of RAS/CBL mutations was found to be associated with adverse phenotypic features and survival outcomes in patients with myelofibrosis.

Rampal Relays the Importance of Genomics in Myelofibrosis

September 24th 2020

Emerging evidence suggests that clinical variables should not be the only consideration in prognostic and risk stratification scoring systems; genomically informed tools carry equal, if not refined, insights regarding patient outcomes.

Dr. Mesa on Emerging Therapies in Myelofibrosis

September 23rd 2020

Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.

Dr. Bose on Novel Agents Under Investigation in Essential Thrombocythemia

September 17th 2020

Prithviraj Bose, MD, discusses novel agents under investigation in essential thrombocythemia.

Dr. Alkharabsheh on Novel Agents Under Exploration in Myelofibrosis

September 16th 2020

Omar Alkharabsheh, MD, discusses novel agents under exploration in the field of myelofibrosis.

Dr. Pemmaraju the Need to Develop Novel Therapies in MPNs

September 15th 2020

Naveen Pemmaraju, MD, discusses the need to develop novel therapies in myeloproliferative neoplasms.

Dr. Spivak on the Prevalence of Polycythemia Vera

September 14th 2020

Jerry Le Pow Spivak, MD, discusses the prevalence of polycythemia vera.

Dr. Mesa on the Emergence of JAK Inhibitors in Myelofibrosis

September 11th 2020

Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis.

Dr. Mascarenhas on the Potential Role of Pacritinib in MPNs

September 10th 2020

John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.

Dr. Mesa on Current Data With Ruxolitinib and Fedratinib in Myelofibrosis

September 9th 2020

Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.